TheraRadar
Clinical-Stage Companies / Dompé Farmaceutici

Dompé Farmaceutici

Pre-Approval PRO BETA
45
Total Trials
13
Phase 3
24
Phase 2
1
Recruiting
440
Score

Pipeline by Phase

Phase 3
13
Phase 2
24
Phase 1
11

Therapeutic Focus

Neurotrophic Keratitis Dry Eye Disease Corneal Ulcer Dry Eye no Condition

Clinical Trials (45)

NCT07395232 Phase 3 RECRUITING

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

Started: 12/1/2025

NCT07519902 Phase 3 NOT YET RECRUITING

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

Started: 4/30/2026

NCT07453888 Phase 3 NOT YET RECRUITING

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Started: 4/30/2026

NCT05254990 Phase 3 TERMINATED

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Started: 4/27/2022

NCT05136170 Phase 3 COMPLETED

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

Started: 1/27/2022

NCT04878055 Phase 3 COMPLETED

Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.

Started: 2/14/2021

NCT05133180 Phase 3 COMPLETED

Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)

Started: 1/19/2022

NCT03836807 Phase 3 COMPLETED

A Study to Assess Efficacy and Tolerability of Ketoprofen 40 mg Granules vs Placebo

Started: 4/4/2018

NCT03837938 Phase 3 COMPLETED

Clinical Trial of Efficacy and Safety of Levopront® 30 mg/5 ml in Patients With Dry Cough

Started: 11/9/2016

NCT01817959 Phase 3 COMPLETED

Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation

Started: 10/1/2012

NCT07503886 Phase 2 NOT YET RECRUITING

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

Started: 5/1/2026

NCT06244316 Phase 2 COMPLETED

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

Started: 1/22/2024

NCT04628481 Phase 2 TERMINATED

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Started: 1/12/2021

NCT05496868 Phase 2 COMPLETED

Add-on Reparixin in Adult Patients With ARDS

Started: 12/6/2022

NCT04899271 Phase 2 TERMINATED

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

Started: 12/14/2020

NCT05368402 Phase 2 TERMINATED

Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.

Started: 9/14/2022

NCT03031470 Phase 2 TERMINATED

Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

Started: 3/10/2015

NCT05212701 Phase 2 WITHDRAWN

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

Started: 4/19/2022

NCT03035864 Phase 2 COMPLETED

A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery

Started: 1/12/2017

NCT03982368 Phase 2 COMPLETED

A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye

Started: 6/10/2019

NCT02101281 Phase 2 COMPLETED

Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye

Started: 1/20/2014

NCT02814838 Phase 2 COMPLETED

A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes

Started: 8/1/2016

NCT04794803 Phase 2 TERMINATED

Reparixin in COVID-19 Pneumonia - Efficacy and Safety

Started: 5/5/2020

NCT05172050 Phase 2 COMPLETED

Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.

Started: 1/22/2021

NCT05035368 Phase 2 WITHDRAWN

Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

Started: 9/30/2021

NCT01571895 Phase 2 TERMINATED

Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid

Started: 2/20/2012

NCT01967888 Phase 2 COMPLETED

Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

Started: 2/1/2014

NCT02227147 Phase 2 COMPLETED

Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK

Started: 2/1/2015

NCT02370238 Phase 2 COMPLETED

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer

Started: 7/29/2015

NCT01861054 Phase 2 TERMINATED

Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer

Started: 2/1/2013

NCT01220856 Phase 2 COMPLETED

Reparixin in Pancreatic Islet Transplantation

Started: 7/28/2010

NCT03019627 Phase 2 COMPLETED

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

Started: 1/20/2017

NCT04802967 Phase 1 COMPLETED

A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males

Started: 2/8/2021

NCT02858193 Phase 1 COMPLETED

Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup

Started: 7/4/2016

NCT04803396 Phase 1 TERMINATED

Ascending Dose Tolerability Trial and PK Assessment in Healthy Volunteers After Single & Multiple Oral Intake of DF2755A

Started: 11/15/2018

NCT01744704 Phase 1 COMPLETED

Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers

Started: 7/1/2012

NCT02350296 Phase 1 COMPLETED

Crossover, Single Dose Randomized, Bioequivalence of Ketoprofen Lysine Salt Immediate Release vs Oral Solution

Started: 11/26/2014

NCT01756456 Phase 1 COMPLETED

Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.

Started: 1/1/2013

NCT02110225 Phase 1 COMPLETED

A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)

Started: 1/1/2014

NCT04854642 Phase 1 COMPLETED

A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers

Started: 10/20/2020

NCT03836859 Phase 1 COMPLETED

Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

Started: 3/30/2018

NCT02001974 Phase 1 COMPLETED

Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)

Started: 2/27/2012

NCT02855450 Phase 1 COMPLETED

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

Started: 12/1/2016

NCT04485546 Phase 4 COMPLETED

Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis

Started: 9/9/2020

NCT06411145 Phase 4 WITHDRAWN

Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis

Started: 4/26/2024

Drug Candidates

Cenegermin DFL24498 Reparixin rhNGF 5 μg/mL rhNGF 10 μg/mL Vehicle (Placebo solution) Vehicle dexamethasone sodium phosphate (DSP) ophthalmic solution Ladarixin Placebo
Activity Status: Active
Last Trial Started: 5/1/2026
Last Trial Ended: 10/21/2025
Trials (12 months): 4
Completed Trials: 29
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.